PRESS RELEASE

ASLAN PHARMACEUTICALS TO PRESENT NEW DATA ON VARLITINIB AT ANNUAL AMERICAN ASSOCIATION FOR CANCER RESEARCH MEETING

Singapore, 23 February, 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that new data relating to varlitinib (ASLAN001) as a single agent in gastric cancer patients have been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2016. This work was done in collaboration with the National Cancer Centre Singapore (NCCS). The meeting will take place from 16 to 20 April 2016 in New Orleans, Louisiana.

Details on the poster presentation are as follows:

**Title:** Varlitinib demonstrates potent antitumor efficacy in patient-derived gastric cancer xenograft models

**Authors:** Huynh T. Hung, Richard Ong, Bertil E. Lindmark, Mark McHale, A.G. Lisa Ooi.

**Poster Number:** 4719

**Date/time:** April 20, 2016; 08:00 ET

**Poster session category:** Experimental and Molecular Therapeutics

**Location:** Convention Center, Halls G-J, Poster Section 16

---

Media contacts

Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 9107 5559
Email: ASLAN@spurwingcomms.com

---

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’S most advanced compounds are in phase 2: varlitinib (ASLAN001), a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET. www.aslanpharma.com